- Home
- LEA vs MRUS Comparison
LEA vs MRUS Comparison
Compare LEA & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEA
- MRUS
- Stock Information
- Founded
- LEA 1917
- MRUS 2003
- Country
- LEA United States
- MRUS Netherlands
- Employees
- LEA N/A
- MRUS N/A
- Industry
- LEA Auto Parts:O.E.M.
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- LEA Consumer Discretionary
- MRUS Health Care
- Exchange
- LEA Nasdaq
- MRUS Nasdaq
- Market Cap
- LEA 5.4B
- MRUS 5.1B
- IPO Year
- LEA N/A
- MRUS 2016
- Fundamental
- Price
- LEA $103.52
- MRUS $95.06
- Analyst Decision
- LEA Buy
- MRUS Buy
- Analyst Count
- LEA 11
- MRUS 18
- Target Price
- LEA $115.91
- MRUS $93.72
- AVG Volume (30 Days)
- LEA 499.9K
- MRUS 2.6M
- Earning Date
- LEA 10-31-2025
- MRUS 10-31-2025
- Dividend Yield
- LEA 2.96%
- MRUS N/A
- EPS Growth
- LEA N/A
- MRUS N/A
- EPS
- LEA 8.57
- MRUS N/A
- Revenue
- LEA $22,889,700,000.00
- MRUS $56,228,000.00
- Revenue This Year
- LEA N/A
- MRUS $51.77
- Revenue Next Year
- LEA $1.85
- MRUS N/A
- P/E Ratio
- LEA $12.15
- MRUS N/A
- Revenue Growth
- LEA N/A
- MRUS 59.77
- 52 Week Low
- LEA $73.85
- MRUS $33.19
- 52 Week High
- LEA $113.10
- MRUS $95.30
- Technical
- Relative Strength Index (RSI)
- LEA 57.89
- MRUS 79.31
- Support Level
- LEA $100.70
- MRUS $94.59
- Resistance Level
- LEA $103.58
- MRUS $95.30
- Average True Range (ATR)
- LEA 2.25
- MRUS 0.35
- MACD
- LEA 0.63
- MRUS -1.00
- Stochastic Oscillator
- LEA 92.20
- MRUS 51.08
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.